This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/drug/DB08819/identifier/kegg-drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB08819/identifier/drugbank/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB08819/identifier/national-drug-code-directory/
n21http://www.drugs.com/
n19http://www.rxlist.com/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/patent/
n26http://linked.opendata.cz/resource/drugbank/drug/DB08819/identifier/chebi/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB08819/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB08819/identifier/pharmgkb/
n17http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB08819/identifier/kegg-compound/
n25http://linked.opendata.cz/resource/drugbank/drug/DB08819/identifier/bindingdb/
n12http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08819
rdf:type
n5:Drug
n5:description
A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Chemically, tafluprost is a fluorinated analog of prostaglandin F2-alpha. Tafluprost was approved for use in the U.S. on February 10, 2012.
n5:dosage
n11:271B56B8-363D-11E5-9242-09173F13E4C5 n11:271B56B9-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Papadia M, Bagnis A, Scotto R, Traverso CE: Tafluprost for glaucoma. Expert Opin Pharmacother. 2011 Oct;12(15):2393-401. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21916788 # Pantcheva MB, Seibold LK, Awadallah NS, Kahook MY: Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Adv Ther. 2011 Sep;28(9):707-15. Epub 2011 Aug 18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21858491 # Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H: Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004 Apr;78(4):767-76. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15037111 # Fukano Y, Kawazu K: Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab Dispos. 2009 Aug;37(8):1622-34. doi: 10.1124/dmd.108.024885. Epub 2009 May 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19477946
n5:group
approved
n5:indication
Tafluprost is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
owl:sameAs
n8:DB08819 n15:DB08819
dcterms:title
Tafluprost
adms:identifier
n4:D06274 n20:PA165958432 n22:Tafluprost n23:C12599 n24:0006-3931-30 n25:50008984 n26:66899 n28:DB08819
n5:mechanismOfAction
Tafluprost acid is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and humans suggest that the main mechanism of action is increased uveoscleral outflow.
n5:patent
n18:5886035
n5:routeOfElimination
Mean plasma tafluprost acid concentrations were below the limit of quantification of the bioanalytical assay (10 pg/mL) at 30 minutes following topical ocular administration of tafluprost 0.0015% ophthalmic solution. In male rats, it was observed that tafluprost was excreted into the feces.
n5:synonym
Zioptan AFP-168
n5:toxicity
Most common ocular adverse reaction is conjunctival hyperemia (range 4% – 20%).
n5:volumeOfDistribution
The highest concentration of tafluprost acid was found in the cornea and conjunctiva.
n9:hasAHFSCode
n10:52-40-28
n13:hasConcept
n14:M0466141
foaf:page
n17:vir1605.shtml n19:zioptan-drug.htm n21:zioptan.html
n5:IUPAC-Name
n6:271B56BE-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B56C4-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B56C3-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B56C0-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B56C1-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B56C2-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B56D4-363D-11E5-9242-09173F13E4C5 n6:271B56BC-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B56D7-363D-11E5-9242-09173F13E4C5 n6:271B56BA-363D-11E5-9242-09173F13E4C5 n6:271B56BD-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B56BB-363D-11E5-9242-09173F13E4C5
n5:pKa
n6:271B56D8-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n12:S01EE05
n5:H-Bond-Acceptor-Count
n6:271B56CA-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B56CB-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B56C5-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B56C6-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B56C8-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B56C7-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B56C9-363D-11E5-9242-09173F13E4C5
n5:absorption
Following instillation, tafluprost is absorbed through the cornea and is hydrolyzed to the biologically active acid metabolite, tafluprost acid. Tafluprost is an ester which makes the drug lipophillic enough to be quickly absorbed through. When administered to the eye, the peak plasma concentration (Cmax) and time to peak plasma concentration (Tmax) of tafluprost acid in healthy subjects was 26 pg/mL and 10 minutes respectively. a AUC, tafluprost acid = 394 pg*min/mL - 432 pg*min/mL.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
209860-87-7
n5:category
n5:Bioavailability
n6:271B56D0-363D-11E5-9242-09173F13E4C5
n5:Boiling-Point
n6:271B56D6-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B56D2-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B56D3-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B56D5-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B56CF-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B56CE-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B56D1-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B56BF-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B56CC-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B56CD-363D-11E5-9242-09173F13E4C5